Mucolipidosis Type IV, caused by mutations in the MCOLN1 gene, currently lacks any disease-modifying treatment. Patients typically experience severe developmental delays, progressive vision loss, and significant neurological impairment, often failing to reach milestones such as walking or speech. For families, the trial represents a shift from managing symptoms to addressing the underlying genetic deficiency.

Randy Gold, president of the ML4 Foundation, spearheaded the effort after his daughter, Eden, was diagnosed with the condition as a toddler. Because the disease is so rare, commercial pharmaceutical interest remained non-existent, forcing the foundation to organize a decade-long development path. This work included preclinical studies at Massachusetts General Hospital and the University of Massachusetts Gene Therapy Center, with manufacturing handled by Andelyn Biosciences.

The experimental therapy utilizes an AAV9 viral vector to deliver a functional copy of the missing gene directly into the central nervous system. While the FDA has cleared the trial, researchers emphasize that the procedure remains entirely experimental. Participants will undergo neurosurgery and immune suppression, with the clinical team monitoring for potential adverse effects and signs of therapeutic benefit. The foundation expects the first patients to be treated before the end of 2026.